TY - JOUR
T1 - Phototherapy for sclerosing skin conditions
AU - Teske, Noelle M.
AU - Jacobe, Heidi T.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Phototherapy is an effective treatment strategy for a variety of sclerosing skin conditions. There are a number of phototherapeutic modalities used for the treatment of sclerosing skin conditions, including ultraviolet (UV)A1, broadband UVA, psoralen plus UVA, and narrowband UVB phototherapy. As controlled trials with validated outcome measures are lacking for these therapies, existing evidence is largely level II for morphea and is even more minimal for scleroderma and other sclerosing disorders (scleroderma, lichen sclerosus, and chronic graft-versus-host disease, among others). Studies do suggest that phototherapy may be effective for many of these disorders, including those that have been unresponsive to other therapies. Phototherapy remains an attractive therapeutic option for patients due to its efficacy and favorable risk-versus-benefit profile. Phototherapy also offers a therapeutic alternative to systemic immunosuppressives for patients who cannot tolerate these medications.
AB - Phototherapy is an effective treatment strategy for a variety of sclerosing skin conditions. There are a number of phototherapeutic modalities used for the treatment of sclerosing skin conditions, including ultraviolet (UV)A1, broadband UVA, psoralen plus UVA, and narrowband UVB phototherapy. As controlled trials with validated outcome measures are lacking for these therapies, existing evidence is largely level II for morphea and is even more minimal for scleroderma and other sclerosing disorders (scleroderma, lichen sclerosus, and chronic graft-versus-host disease, among others). Studies do suggest that phototherapy may be effective for many of these disorders, including those that have been unresponsive to other therapies. Phototherapy remains an attractive therapeutic option for patients due to its efficacy and favorable risk-versus-benefit profile. Phototherapy also offers a therapeutic alternative to systemic immunosuppressives for patients who cannot tolerate these medications.
UR - http://www.scopus.com/inward/record.url?scp=85019750427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019750427&partnerID=8YFLogxK
U2 - 10.1016/j.clindermatol.2016.05.012
DO - 10.1016/j.clindermatol.2016.05.012
M3 - Article
C2 - 27638441
AN - SCOPUS:85019750427
SN - 0738-081X
VL - 34
SP - 614
EP - 622
JO - Clinics in Dermatology
JF - Clinics in Dermatology
IS - 5
ER -